ET Prime interviews AUM Biosciences on its game-changing Asia-to-Global vision to tackle Asia‘s oncology challenges

AUM Biosciences battles the clinical research bias of giants like Roche, Pfizer, Merck and Novartis with its ‘Asia to Global’ approach by responding to Asia’s exploding cancer crisis with targeted treatments in Asia for Asians, before looking beyond the continent. 

 

 

Read more here.